SCHEMBL13833795

SCHEMBL13833795

CC(=O)Nc1oc2ccccc2c1-c1nc2ccccc2s1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 6/20 0.55
▸ POLB P06746 2/20 0.55
▸ TDP1 Q9NUW8 1/20 0.55
▸ L3MBTL1 Q9Y468 1/20 0.55
▸ ADORA1 P30542 1/20 0.51
▸ DYRK1A Q13627 1/20 0.51
▸ KDM4E B2RXH2 5/20 0.51
▸ RAB9A P51151 4/20 0.51
▸ SMN1; SMN2 Q16637 4/20 0.51
▸ NPC1 O15118 3/20 0.51
▸ GAA P10253 1/20 0.51
▸ APEX1 P27695 6/20 0.50
▸ THRB P10828 1/20 0.50
▸ MEN1 O00255 2/20 0.49
▸ KMT2A Q03164 2/20 0.49
▸ TP53 P04637 2/20 0.49
▸ HPGD P15428 2/20 0.48
▸ ALDH1A1 P00352 2/20 0.48
▸ CTDSP1 Q9GZU7 1/20 0.48
▸ USP2 O75604 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14788137 0.84 KDM4E (0.47) MAPTPOLBTDP1L3MBTL1ADORA1
SCHEMBL13833847 0.81 ADORA1 (0.51) MAPTPOLBTDP1L3MBTL1ADORA1
SCHEMBL13833700 0.78 MAPT (0.55) MAPTPOLBTDP1L3MBTL1ADORA1
SCHEMBL13833660 0.78 MAPT (0.66) MAPTPOLBTDP1L3MBTL1ADORA1
SCHEMBL13833704 0.77 MAPT (0.60) MAPTPOLBTDP1L3MBTL1KDM4E
SCHEMBL13833701 0.74 KDM4E (0.53) MAPTL3MBTL1KDM4ERAB9ASMN1; SMN2
SCHEMBL14788083 0.73 APEX1 (0.49) MAPTPOLBTDP1L3MBTL1ADORA1
SCHEMBL6510910 0.73 PIK3CD (0.53) MAPTPOLBKDM4ERAB9ASMN1; SMN2
SCHEMBL13833777 0.72 MAPT (0.58) MAPTPOLBTDP1L3MBTL1ADORA1
SCHEMBL14791461 0.71 APEX1 (0.48) MAPTPOLBTDP1L3MBTL1ADORA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130072473-A1 COMPOUNDS FOR TREATING PROTEIN FOLDING DISORDERS PROTEOSTASIS THERAPEUTICS, INC. 2013-03-21 — — US disclosed
US-20130072473-A1 COMPOUNDS FOR TREATING PROTEIN FOLDING DISORDERS PROTEOSTASIS THERAPEUTICS, INC. 2013-03-21 — — US disclosed
WO-2012154888-A1 COMPOUNDS FOR TREATING PROTEIN FOLDING DISORDERS PROTEOSTASIS THERAPEUTICS, INC. (US) 2012-11-15 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130072473-A1 COMPOUNDS FOR TREATING PROTEIN FOLDING DISORDERS HSPA5, PSMG3, VCP MAPT 221/4885POLB 2314/4885TDP1 1104/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback